Investor Relations

OUR LEAD ONCOLOGY CANDIDATE, OFRA-VEC, IS CURRENTLY BEING EVALUATED IN OUR OVAL PHASE 3 REGISTRATION-ENABLING CLINICAL TRIAL IN OVARIAN CANCER. READOUT OF OVAL PFS CO-PRIMARY ENDPOINT IS EXPECTED IN THE THIRD QUARTER OF 2022. FOR ADDITIONAL INFORMATION AND CATALYSTS, SEE OUR CORPORATE PRESENTATION.

Press Releases

May 31, 2022
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
Read More
May 17, 2022
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Read More

Events & Presentations

July 7, 2022 at 4:00 PM IDT
Annual General Meeting of shareholders of Vascular Biogenics Ltd.
Read More
June 8, 2022 at 3:00 PM EDT
Jefferies Healthcare Conference
Read More

Corporate Presentation

Company Presentation June 2022
July 1, 2022 2:17 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart